Cyberknife Center Munich Grosshadern, Munich, Germany.
Urol Oncol. 2013 May;31(4):455-60. doi: 10.1016/j.urolonc.2011.02.023. Epub 2011 Apr 11.
To determine the safety and feasibility after image-guided single fraction robotic stereotactic radiosurgery (SRS) in patients with bone metastases of prostate cancer.
Forty patients with 64 bone metastases of prostate cancer were prospectively enrolled in a single center study and underwent 54 consecutive outpatient single session SRS procedures during a 4-year period. F-18 choline PET/CT in addition to standard CT imaging was done prior to SRS in all patients. Nineteen patients were under anti-androgen therapy, 8 patients had undergone chemotherapy before SRS. Overall survival and freedom from local tumor recurrence was analyzed with the Kaplan-Meier method.
Mean follow-up was 14 months (3-48 months). Seventy-five percent of patients had a single bone metastasis. The median tumor volume was 13 cc. The mean prescribed tumor dose was 20.2 Gy (16.5-22 Gy). Eight patients had died at the time point of the data analysis. The actuarial 6-months, 12-months, and 24-months local tumor control rate was 95.5% (95% CI: 83.0-98.8) as measured by MRI and PET CT imaging. The median initial PSA before SRS was 5.4 ng/dl (CI: 1.4-8.2) and dropped to 2.7 ng/dl (CI: 0.14-10) after 3 months. One case of progressive neurological deficits was documented.
This first report on single session, image-guided robotic SRS documents a safe, feasible, and patient-friendly treatment option in selected patients with bone metastases of prostate cancer.
确定前列腺癌骨转移患者行影像引导单次分割机器人立体定向放射外科治疗(SRS)的安全性和可行性。
在单中心研究中,前瞻性纳入了 40 例 64 处前列腺癌骨转移患者,在 4 年期间共进行了 54 例连续的门诊单次 SRS 治疗。所有患者均在 SRS 前行 F-18 胆碱 PET/CT 结合标准 CT 成像。19 例患者接受抗雄激素治疗,8 例患者在 SRS 前接受过化疗。采用 Kaplan-Meier 法分析总生存期和局部肿瘤无复发生存率。
中位随访时间为 14 个月(3-48 个月)。75%的患者仅有单个骨转移灶,肿瘤体积中位数为 13cc,中位肿瘤处方剂量为 20.2Gy(16.5-22Gy)。在数据分析时,8 例患者已死亡。MRI 和 PET CT 影像学评估的 6 个月、12 个月和 24 个月局部肿瘤控制率的累积生存率分别为 95.5%(95%可信区间:83.0-98.8)。SRS 前初始 PSA 的中位数为 5.4ng/dl(可信区间:1.4-8.2),3 个月后降至 2.7ng/dl(可信区间:0.14-10)。记录到 1 例进行性神经功能缺损病例。
这是首例关于单次分割、影像引导机器人 SRS 的报告,证明了在选择的前列腺癌骨转移患者中,这是一种安全、可行且对患者友好的治疗选择。